Enterprise Value
5.55M
Cash
1.337M
Avg Qtr Burn
-9.248M
Short % of Float
11.32%
Insider Ownership
8.07%
Institutional Own.
2.27%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MB-107 Details X-Linked severe combined immunodeficiency | Phase 2 Update | |
MB-207 Details X-Linked severe combined immunodeficiency, Myelofibrosis | Phase 2 Update | |
MB-106 (CD20) (Mustang Multicenter) Details Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Cancer, Lymphoma | Phase 2 Initiation | |
MB-106 (CD20) (Fred Hutch) Details Lymphoma, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Epstein-Barr virus, Multiple sclerosis, Cancer, Waldenstrom macroglobulinemia | Phase 1/2 Update | |
MB-101 (IL-13Ra2) + MB-108 Details Medulloblastoma, Ependymoma, Glioblastoma, Leptomeningeal brain tumors | Phase 1 Initiation | |
MB-103 (HER2) Details Glioblastoma, Metastatic breast cancer to brain, Cancer | Failed Discontinued | |
MB-104 Details Multiple myeloma, Cancer, Solid tumor/s | Failed Discontinued | |
MB-105 (PSCA) Details Prostate cancer, Multiple myeloma, Cancer | Failed Discontinued | |
MB-102 (CD123) Details High risk myelodysplastic syndromes , Blastic plasmacytoid dendritic cell neoplasm, Acute myeloid leukemia, Cancer | Failed Discontinued | |
MB-110 (LV-RAG1) Details Severe combined immunodeficiency due to complete RAG1/2 deficiency | Failed Discontinued |